Cystatin C as a Predictor of In-Hospital Mortality After Exacerbation of COPD

References

1. 1.↵
   1. Murray CJ,
   2. Lopez AD

   . Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997;349(9064):1498–1504.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Sin DD,
   2. Anthonisen NR,
   3. Soriano JB,
   4. Agusti AG

   . Mortality in COPD: role of comorbidities. Eur Respir J 2006;28(6):1245–1257.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Holguin F,
   2. Folch E,
   3. Redd SC,
   4. Mannino DM

   . Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005;128(4):2005–2011.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Connors AF Jr..,
   2. Dawson NV,
   3. Thomas C,
   4. Harrell FE Jr..,
   5. Desbiens N,
   6. Fulkerson WJ,
   7. et al

   . Outcomes following acute exacerbation of severe chronic obstructive lung disease: the SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154(4 Pt 1):959–967.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Pingleton SK

   . Complications of acute respiratory failure. Am Rev Respir Dis 1988;137(6):1463–1493.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Gjerde B,
   2. Bakke PS,
   3. Ueland T,
   4. Hardie JA,
   5. Eagan TM

   . The prevalence of undiagnosed renal failure in a cohort of COPD patients in western Norway. Respir Med 2012;106(3):361–366.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Kiyosue A,
   2. Hirata Y,
   3. Ando J,
   4. Fujita H,
   5. Morita T,
   6. Takahashi M,
   7. et al

   . Plasma cystatin C concentration reflects the severity of coronary artery disease in patients without chronic kidney disease. Circ J 2010;74(11):2441–2447.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Hojs R,
   2. Bevc S,
   3. Ekart R,
   4. Gorenjak M,
   5. Puklavec L

   . Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. Clin Nephrol 2008;70(1):10–17.

   OpenUrlPubMed
9. 9.↵
   1. Keller T,
   2. Messow CM,
   3. Lubos E,
   4. Nicaud V,
   5. Wild PS,
   6. Rupprecht HJ,
   7. et al

   . Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J 2009;30(3):314–320.

   OpenUrlAbstract/FREE Full Text
10. 10.
    1. Ichimoto E,
    2. Jo K,
    3. Kobayashi Y,
    4. Inoue T,
    5. Nakamura Y,
    6. Kuroda N,
    7. et al

    . Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction. Circ J 2009;73(9):1669–1673.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Taglieri N,
    2. Fernandez-Berges DJ,
    3. Koenig W,
    4. Consuegra-Sanchez L,
    5. Fernandez JM,
    6. Robles NR,
    7. et al

    . Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis 2010;209(1):300–305.

    OpenUrlCrossRefPubMed
12. 12.
    1. Shlipak MG,
    2. Katz R,
    3. Fried LF,
    4. Jenny NS,
    5. Stehman-Breen C,
    6. Newman AB,
    7. et al

    . Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 2005;45(2):268–271.

    OpenUrlPubMed
13. 13.↵
    1. Lassus J,
    2. Harjola VP,
    3. Sund R,
    4. Siirilä-Waris K,
    5. Melin J,
    6. Peuhkurinen K,
    7. et al

    . Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007;28(15):1841–1847.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Zhang M,
    2. Fu SH,
    3. Cui H,
    4. Zhu BP,
    5. Liu L,
    6. Wang DL

    . Serum cystatin C and indices of lung function in elderly Chinese men with chronic obstructive pulmonary disease. Aging Clin Exp Res 2014;26(2):193–199.

    OpenUrlPubMed
15. 15.↵
    1. Pérez-Calvo JI,
    2. Sánchez-Marteles M,
    3. Ruiz-Ruiz FJ,
    4. Morales-Rull JL,
    5. Nieto-Rodríguez JA

    . Differential prognostic utility of NTproBNP and Cystatin C in patients with acute exacerbation of chronic pulmonary disease. JRSM Short Rep 2010;1(5):44.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Levey AS,
    2. Bosch JP,
    3. Lewis JB,
    4. Greene T,
    5. Rogers N,
    6. Roth D

    . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130(6):461–470.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. [Guidelines for the diagnosis and management of chronic heart failure]. Zhonghua Xin Xue Guan Bing Za Zhi 2007;35(12):1076–1095.

    OpenUrlPubMed
18. 18.↵
    1. Lassus J,
    2. Harjola VP

    . Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev 2012;17(2):251–261.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Urbonaviciene G,
    2. Shi GP,
    3. Urbonavicius S,
    4. Henneberg EW,
    5. Lindholt JS

    . Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. Atherosclerosis 2011;216(2):440–445.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Balta S,
    2. Demirkol S,
    3. Ay SA,
    4. Cakar M,
    5. Sarlak H,
    6. Celik T

    . Serum cystatin-C levels correlate with endothelial dysfunction in patients with the metabolic syndrome. J Intern Med 2013;274(2):200–201.

    OpenUrlPubMed
21. 21.↵
    1. Carrasco-Sánchez FJ,
    2. Galisteo-Almeda L,
    3. Páez-Rubio I,
    4. Martínez-Marcos FJ,
    5. Camacho-Vázquez C,
    6. Ruiz-Frutos C,
    7. Pujol-Da La Llave E

    . Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail 2011;17(1):31–38.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Akgul O,
    2. Uyarel H,
    3. Ergelen M,
    4. Pusuroglu H,
    5. Gul M,
    6. Turen S,
    7. et al

    . Predictive value of elevated cystatin C in patients undergoing primary angioplasty for ST-elevation myocardial infarction. J Crit Care 2013;28(5):882.e13–882.e20

    OpenUrl
23. 23.↵
    1. Woitas RP,
    2. Kleber ME,
    3. Meinitzer A,
    4. Grammer TB,
    5. Silbernagel G,
    6. Pilz S,
    7. et al

    . Cystatin C is independently associated with total and cardiovascular mortality in individuals undergoing coronary angiography: the Ludwigshafen risk and cardiovascular health (LURIC) study. Atherosclerosis 2013;229(2):541–548.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Rokadia HK,
    2. Agarwal S

    . Serum cystatin C and emphysema: results from the National Health and Nutrition Examination Survey (NHANES). Lung 2012;190(3):283–290.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Takeyabu K,
    2. Betsuyaku T,
    3. Nishimura M,
    4. Yoshioka A,
    5. Tanino M,
    6. Miyamoto K,
    7. Kawakami Y

    . Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Eur Respir J 1998;12(5):1033–1039.

    OpenUrlAbstract
26. 26.↵
    1. Li J,
    2. Zhao HJ,
    3. Wang FY,
    4. Dong HM,
    5. Cai SX

    . [Risk factors for in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease]. Zhonghua Yi Xue Za Zhi 2013;93(18):1374–1377.

    OpenUrlPubMed
27. 27.↵
    1. Fruchter O,
    2. Yigla M

    . Predictors of long-term survival in elderly patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Respirology 2008;13(6):851–855.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Sarnak MJ,
    2. Katz R,
    3. Stehman-Breen CO,
    4. Fried LF,
    5. Jenny NS,
    6. Psaty BM,
    7. et al

    . Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005;142(7):497–505.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    1. Ix JH,
    2. Shlipak MG,
    3. Chertow GM,
    4. Ali S,
    5. Schiller NB,
    6. Whooley MA

    . Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail 2006;12(8):601–607.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. William Macnee,
    2. Jørgen Vestbo,
    3. Alvar Agusti

    . 43 - COPD: Pathogenesis and Natural History. Murray and Nadel's Textbook of Respiratory Medicine (Sixth Edition), Volume 1, 2016, Pages 751–766.e7.

    OpenUrl
31. 31.↵
    1. Finlay GA,
    2. O'Driscoll LR,
    3. Russell KJ,
    4. D'Arcy EM,
    5. Masterson JB,
    6. FitzGerald MX,
    7. O'Connor CM

    . Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997;156(1):240–247.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.↵
    1. Díez J

    . Altered degradation of extracellular matrix in myocardial remodelling: the growing role of cathepsins and cystatins. Cardiovasc Res 2010;87(4):591–592.

    OpenUrlFREE Full Text